-

01:26:02 AM

AUTL Stock News

AUTL - Autolus Therapeutics plc

01/30/23 1:40 PM

Nasdaq : AUTL

Autologous Cell Therapy Market Report 2022: Sector to Reach $24.31 Billion by 2030 at a 19.4% CAGR

The "Autologous Cell Therapy Market Size, Share& Trends Analysis Report By Source, By Application, By End-use, By Region, And Segment Forecasts, 2022- 2030" report has been added to ResearchAndMarkets.com' s offering. The global autologous cell therapy market size is expected to reach USD 24.31 billion by 2030. In June 2020, Chiesi Group and Holostem Terapie Avanzate...

RHEA-AI

neutral

01/20/23 7:00 AM

Nasdaq : AUTL

Autolus Therapeutics announces Board changes

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces two changes to the company’s Board of Directors. The company’s non-executive Chairman, John H Johnson,

RHEA-AI

neutral

01/09/23 7:00 AM

Nasdaq : AUTL

Autolus Therapeutics Announces Collaboration with Cabaletta Bio for Use of Autolus’ Safety Switch System in Cell Therapies for Autoimmune Disease

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it has entered into a non-exclusive license agreement with Cabaletta Bio, Inc (Nasdaq: CABA).

RHEA-AI

neutral

12/21/22 4:01 PM

Nasdaq : AUTL

Autolus Announces Partial Exercise of Underwriters' Option to Purchase Additional ADSs

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced today that the underwriters of its previously announced public offering of American Depositary Shares, or

RHEA-AI

neutral

12/12/22 10:00 AM

Nasdaq : AUTL

conferencesclinical trial

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022

Obe-cel: 35% of relapsed/refractory adult B-ALL patients in the ALLCAR19 trial remain in complete remission at a median follow up of three years without the need for additional anti-leukemia therapy Obe-cel: continues to show high level of sustained clinical activity in B-NHL patients AUTO1/22: no

RHEA-AI

neutral

12/08/22 9:11 PM

Nasdaq : AUTL

offering

Autolus Announces Pricing of Public Offering

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of its previously announced underwritten public offering in the United States of

RHEA-AI

neutral

12/08/22 4:03 PM

Nasdaq : AUTL

offering

Autolus Announces Proposed Public Offering in the United States

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has commenced an underwritten public offering of American Depositary Shares (“ADSs”), each

RHEA-AI

neutral

12/08/22 4:02 PM

Nasdaq : AUTL

Autolus Therapeutics to Receive $70 Million in Milestone Payments from Blackstone Life Sciences

Development milestone of $35m achieved earlier than anticipated as a result of the positive interim analysis of Autolus’ pivotal FELIX Phase 2 trial, announced in a separate press release today Manufacturing milestone of $35m achieved as a result of completion of planned activities supporting the

RHEA-AI

very positive

12/08/22 4:01 PM

Nasdaq : AUTL

clinical trial

Autolus Therapeutics announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis

Obe-cel demonstrated Overall Remission Rate (ORR) of 70% in interim analysis of 50 patients with relapsed/refractory (r/r) adult Acute Lymphoblastic Leukemia (ALL) Encouraging safety data observed, with 3% ≥Grade 3 Cytokine Release Syndrome (CRS) and 8% ≥Grade 3 Immune effector cell-associated

RHEA-AI

neutral

11/30/22 7:00 AM

Nasdaq : AUTL

Autolus Therapeutics announces handover of first clean rooms of new Stevenage, UK, manufacturing facility

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the handover of the first of three clean rooms forming the basis of its new commercial

RHEA-AI

very positive

1 2 3 4 5 6 7 8 9 Next

AUTL Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.autolus.com
Security nameAutolus Therapeutics plc - ADR
Issue typead
SectorManufacturing
Sic code2836
Employees2021
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
AddressScale Space Building
Address2White City
StateLondon
City58 Wood Lane
ZipW12 7RZ
CountryUnited Kingdom
Phone442038296230

About Autolus Therapeutics plc

Autolus Therapeutics plcis a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.